Skip to content

Epidemiology of psoriasis in Germany–analysis of secondary health insurance data

Epidemiology of psoriasis in Germany--analysis of secondary health insurance data 1

Epidemiology of Psoriasis in Germany Analysis of Secondary Health Insurance Data on ResearchGate, the professional network for scientists. Analysis of the health insurance data showed that juvenile psoriasis is associated with a range of comorbidities. Epidemiology of psoriasis in Germany–analysis of secondary health insurance data. Sick fund analyses revealed that in Germany, psoriasis health care is provided to an almost similar extent by dermatologists and general practitioners (GP) (40 50 each) 6.

Epidemiology of psoriasis in Germany--analysis of secondary health insurance data 2Schfer I, Rustenbach SJ, Radtke M, Augustin J, Glaeske G, Augustin M. Epidemiology of Psoriasis in Germany Analysis of Secondary Health Insurance Data. One incidence study found that psoriasis patients have a hazard ratio of 1.18 (95 CI 1. Many of these studies assessed obesity as a secondary outcome in conjunction with prevalence of metabolic syndrome, but most studies adjusted for obesity independently. Co-morbidity and age-related prevalence of psoriasis: analysis of health insurance data in Germany. Up to two third of patients with psoriasis develop nail changes. Epidemiology of psoriasis in Germany–analysis of secondary health insurance data.

Health Improvement Network database, a population-representative electronic health records database from the United Kingdom, from June 27, 1994, through January 15, 2013. Secondary analysis: lifetime exposure. No studies to date have assessed incidence of metabolic syndrome among patients with psoriasis. Keywords: psoriasis, epidemiology, comorbidities, health services accessibility, health care disparities, insurance, health care costs. The objective of this review is to summarize Brazilian data concerning the epidemiology, comorbidities, and treatment of psoriasis. Nevertheless, cases of secondary leprosy were described after psoriasis treatment with infliximab and etanercept.

John Libbey Eurotext

Methotrexate Polyglutamates as a Marker of Clinical Response and Toxicity in the Treatment of Psoriasis (MTXPG) 3

Jama Network